期刊文献+

500例精神病患者服用抗精神病药物后致白细胞减少的回顾性分析 被引量:3

Leukopenia induced by antipsychotic drugs:a retrospective analysis based on 500 cases of psychosis
下载PDF
导出
摘要 目的探讨精神病患者服用抗精神病药物后致白细胞减少的特点,为临床用药提供参考。方法收集医院收治的500例各类精神病患者的临床资料,回顾患者基本资料、用药种类、用药方法、白细胞减少程度的分布情况、白细胞减少的时间和临床症状等。结果 500例精神病患者中白细胞减少者144例(28.8%),其中白细胞计数3~4×109/L者98例(68.1%),2~3×109/L者42例(29.2%),<2×109/L者4例(2.8%);服用第一代药物致白细胞减少者的比例高于服用第二代药物者,联合用药致白细胞减少者的比例高于单一用药者,差异均有统计学意义(均P<0.05)。治疗后,所有患者白细胞均恢复至正常范围,无严重感染、败血症等严重后果。结论部分精神病患者服用抗精神病药物后可导致白细胞减少,以服用第一代药物者和联合用药者居多。 Objective To understand the mechanism of leukopenia induced by antipsychotic drugs with a view to improvingclinical medication for the patients.Method The clinical data of500patients with psychosis were firstly collected.The basic data,types of drugs,methods of administration,distribution of leukopenia,time and clinical symptoms of leukopenia were then systematically reviewed.Findings144cases(28.8%)of leukopenia were found ofthe500patients with psychosis,which included98cases(68.1%)of white blood cell count of3~4×109/L,42cases(29.2%)of2~3×109/L,<2×109/L in4cases(2.8%).The proportion of leukopenia in the first generation of drugs was significantly higher than that in the second generation,and the proportion of leukopenia with combined drugs was significantly higher than that of single drug,which were statistically significant(all P<0.05).All leukopenia were not serious infection,sepsis and other serious consequences.Conclusion A subset of psychiatric patients can lead to leukopenia after taking antipsychotic drugs.It is mainly due to the use of first-generation drugs and combined drugs.
作者 王仙凤 张瑨 WANG Xian-feng;ZHANG Jin(Clinical Laboratory, Lishui Second People's Hospital, Lishui323000;Department of Psychiatry, Jinhua Second Hospital, Jinhua321016, China)
出处 《健康研究》 CAS 2018年第1期76-78,共3页 Health Research
关键词 精神病 抗精神病药物 白细胞减少 psychosis antipsychotic drugs leukopenia
  • 相关文献

参考文献6

二级参考文献62

  • 1司天梅,舒良,于欣,马崔,王高华,白培深,刘协和,纪丽萍,师建国,陈宪生,梅其一,栗克清,张鸿燕,马弘.10省市抗精神病药使用现况的调查[J].中华精神科杂志,2004,37(3):152-155. 被引量:95
  • 2舒良主编.精神分裂症防治指南.北京:北京大学医学出版社.2007:127
  • 3McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev, 2008, 30:67-76.
  • 4Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry, 2004, 161 ( 2 Suppl) : 1-56.
  • 5Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull, 2004, 30:193-217.
  • 6Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull, 2009, 35:443-457.
  • 7McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry, 2003, 64:984-989.
  • 8Ponto T, Ismail NI, Abdul Majeed AB, et al. A prospective study on the pattern of medication use for schizophrenia in the outpatient pharmacy department, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia. Methods Find Exp Clin Pharmacol,2010,32: 427-432.
  • 9Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization : comparing monotherapy with polypharmaey and augmentation. Curt Med Chem,2004,11:313-327.
  • 10Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry,2005, 39(1-2) :1-30.

共引文献45

同被引文献25

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部